The company's stock is nearly 50 per cent higher than in June 2014, when Sikka took over, and the momentum favours it over peers
73 such listed entities here, against 14 in China, six in Japan and two in America; analysts caution, for reasons, against reading too much into this
Rs 4,300-crore dividend tax blow for promoters
Longest period of expansion in price-earning ratio since 1996
67 companies with total debt of Rs 5.65 lakh cr were either loss-making or didn't generate enough profit to cover interest cost in FY15
Big-ticket buyouts at the peak of valuation cycle failed to live up to the hype; smaller deals did better
Premium valuations era started in 2006 and went hand in hand with decline in the US interest rates
This is largely because of a sharp cut in capex and investments rather than any material improvement in cash flow generation from operations
The company may not recover the funds invested to acquire and sustain Sylvania since 2007
In FY15, every incremental rupee of money supply generated just Rs 1.2 of incremental gross domestic product
Sources say Alkem Laboratories' Rs 1,350-crore IPO and Dr Lal PathLabs' Rs 633-crore IPO will open from December 7 to 9
Share of IT, pharma, and FMCG companies in Sensex to rise to 38% next month; manufacturing losing sheen
Banks and finance firms accounted for 31% of BSE 500 companies' profits in 2014-15 versus their 20.6% profit share in S&P 500
Core operating margins in July-Sept quarter down 165 basis points, sequentially
Net sales growth decline 4.4% in September quarter, the second worst in eight years; net profit grows at the fastest pace in four quarters
Promoters' holding in private sector BSE 500 companies declined to 43.4% in Sept
Developed countries see double-digit growth, emerging ones witness contraction
Thanks to the recent rally, now the index is more expensive than it was at 2014-end or when it hit a life-time high in January
Poor global demand might make it tough for India to crank its growth engine